Sign in or create an account to add this stock to your watchlist.
About Akers Biosciences (NASDAQ:AKER)
Akers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States and internationally. The company's marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. Its marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol ?Check', a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app. The company's pipeline products comprise Breath Diabetic Ketoacidosis, a disposable breath ketone device for diabetic monitoring; Breath PulmoHealth ?Check', a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; PIFA PLUSS Chlamydia, a rapid test for sexually transmitted diseases; and BreathScan KetoChek, a breath test for ketosis using the Lync reader and digital app. Akers Biosciences, Inc. was founded in 1989 and is headquartered in Thorofare, New Jersey.
Industry, Sector and Symbol
Industry Diagnostic substances
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$3.93 million
Price / Sales12.39
Price / CashN/A
Book Value$0.17 per share
Price / Book3.49
EPS (Most Recent Fiscal Year)N/A
Return on Equity-104.85%
Return on Assets-77.26%
Akers Biosciences (NASDAQ:AKER) Frequently Asked Questions
What is Akers Biosciences' stock symbol?
Akers Biosciences trades on the NASDAQ under the ticker symbol "AKER."
How were Akers Biosciences' earnings last quarter?
Akers Biosciences (NASDAQ:AKER) released its quarterly earnings data on Tuesday, April, 3rd. The medical instruments supplier reported ($0.23) earnings per share for the quarter. The medical instruments supplier had revenue of $1.39 million for the quarter. Akers Biosciences had a negative net margin of 147.74% and a negative return on equity of 104.85%. View Akers Biosciences' Earnings History.
When is Akers Biosciences' next earnings date?
Are investors shorting Akers Biosciences?
Akers Biosciences saw a drop in short interest in April. As of April 13th, there was short interest totalling 10,674,836 shares, a drop of 12.7% from the March 30th total of 12,222,439 shares. Based on an average daily volume of 11,795,378 shares, the short-interest ratio is currently 0.9 days. Approximately 14.0% of the company's shares are short sold.
Who are some of Akers Biosciences' key competitors?
Some companies that are related to Akers Biosciences include Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Vermillion (VRML), ImmuCell (ICCC), Achieve Life Sciences (ACHV), ARCA biopharma (ABIO), GeneNews (GNWSF), FluoroPharma Medical (FPMI), BG Medicine (BGMD), Response Genetics (RGDXQ) and Palatin Technologies (PTN).
Who are Akers Biosciences' key executives?
Akers Biosciences' management team includes the folowing people:
- Dr. Raymond F. Akers Jr., Co-Founder, Exec. Chairman, Chief Scientific Director & Sec. (Age 60)
- Mr. John J. Gormally, CEO & Director (Age 62)
- Mr. Gary M. Rauch, VP of Fin. & Treasurer (Age 62)
- Mr. Douglas Carrara, Sr. VP of Global Marketing & Commercial Operations
- Ms. Pamela E. Hibler, VP of Sales & Distribution
Has Akers Biosciences been receiving favorable news coverage?
News stories about AKER stock have been trending somewhat positive on Wednesday, Accern reports. The research group identifies negative and positive media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Akers Biosciences earned a media sentiment score of 0.22 on Accern's scale. They also gave news articles about the medical instruments supplier an impact score of 47.88 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Akers Biosciences' major shareholders?
Which major investors are buying Akers Biosciences stock?
How do I buy shares of Akers Biosciences?
Shares of AKER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akers Biosciences' stock price today?
One share of AKER stock can currently be purchased for approximately $0.5940.
How big of a company is Akers Biosciences?
Akers Biosciences has a market capitalization of $53.87 million and generates $3.93 million in revenue each year. Akers Biosciences employs 32 workers across the globe.
How can I contact Akers Biosciences?
Akers Biosciences' mailing address is 201 GROVE RD, THOROFARE NJ, 08086. The medical instruments supplier can be reached via phone at 856-848-2116 or via email at [email protected]
MarketBeat Community Rating for Akers Biosciences (AKER)MarketBeat's community ratings are surveys of what our community members think about Akers Biosciences and other stocks. Vote "Outperform" if you believe AKER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKER will underperform the S&P 500 over the long term. You may vote once every thirty days.
Akers Biosciences (NASDAQ:AKER) Analyst Ratings History
(Data available from 5/23/2016 forward)
|Date||Brokerage||Action||Rating||Price Target||Impact on Share Price||Details|
Akers Biosciences (NASDAQ:AKER) Earnings History and Estimates Chart
Akers Biosciences (NASDAQ AKER) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/29/2018|| || || || || || || || |
|4/3/2018||Q4 2017||($0.23)||$1.39 million||View||N/A|
|4/11/2017||Q4 2016||($0.20)||$0.65 million||View||N/A|
|5/12/2016||Q1 2016||($0.28)||$0.74 million||View||N/A|
|3/30/2016||Q4 2015||($0.69)||$0.47 million||View||N/A|
|8/18/2015||Q215||($0.41)||$1.35 million||$0.97 million||View||Listen|
|5/14/2015||Q115||($0.10)||($0.26)||$2.00 million||$0.51 million||View||Listen|
|3/23/2015||Q4 2014||($0.19)||$1.45 million||View||N/A|
|11/13/2014||Q314||($0.17)||($0.23)||$1.40 million||$453.30 million||View||N/A|
|8/12/2014||Q2 2014||($0.16)||($0.10)||$1.35 million||View||N/A|
|5/14/2014||Q1 2014||($0.14)||$1.17 million||View||N/A|
Akers Biosciences (NASDAQ:AKER) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Akers Biosciences (NASDAQ AKER) News Headlines
|Akers Biosciences (AKER) Scheduled to Post Earnings on Monday|
www.americanbankingnews.com - May 7 at 4:26 AM
|BRIEF-Akers Biosciences Says Terminated Raymond Akers Positions As Executive Chairman|
www.reuters.com - April 27 at 8:35 AM
|Pre-Market Technical Scan on Medical Supplies Equities -- Akers Biosciences, Antares Pharma, Baxter, and Becton ...|
www.prnewswire.com - April 27 at 8:35 AM
|Short Interest in Akers Biosciences (AKER) Declines By 12.7%|
www.americanbankingnews.com - April 27 at 1:24 AM
|Akers Biosciences Strips Chairman Raymond Akers Of Executive Duties|
www.morningstar.co.uk - April 26 at 8:22 AM
|BRIEF-Akers Biosciences Says Appointed Richard Carlyle Tarbox III As Interim Non-Executive Chairman|
www.reuters.com - April 26 at 8:22 AM
|BRIEF-Akers Biosciences Expands Outsourced US Distribution Capabilities For Heparin PF4 Rapid Test|
www.reuters.com - April 14 at 8:29 AM
|Akers Biosciences To Raise USD750,000 Following Warrants Exercise (ALLISS)|
www.morningstar.co.uk - April 13 at 5:26 PM
|BRIEF-Akers Biosciences Expands Outsourced U.S. Distribution Capabilities For Heparin PF4 Rapid Test|
www.reuters.com - April 12 at 8:48 AM
|Akers Bio beefs up U.S. distribution for Heparin PF4 rapid test; shares up 7% premarket|
seekingalpha.com - April 12 at 8:48 AM
|Akers Biosciences Expands Outsourced US Distribution Capabilities for Heparin PF4 Rapid Test|
finance.yahoo.com - April 12 at 8:48 AM
|Form 4/A Akers Biosciences, Inc. For: Oct 17 Filed by: Gormally John J|
www.streetinsider.com - April 11 at 8:37 AM
|Akers Biosciences Raises USD814,444 After Warrants Exercise (ALLISS)|
www.morningstar.co.uk - April 6 at 5:37 PM
|Akers Biosciences (AKER) Reports FY17 Revenue of $3.93M|
www.streetinsider.com - April 4 at 8:28 AM
|Akers Biosciences 2017 Revenue Rises But Loss Widens On Higher Costs|
www.lse.co.uk - April 3 at 5:29 PM
|Akers Biosciences (AKER) CEO John Gormally on Q4 2017 Results - Earnings Call Transcript|
seekingalpha.com - April 3 at 5:29 PM
|Akers Biosciences down 15% premarket on FY 2017 results|
seekingalpha.com - April 3 at 8:30 AM
|Akers Biosciences Inks US Distribution Pact With Diagnostica Stago (ALLISS)|
www.morningstar.co.uk - March 26 at 5:12 PM
|Akers Biosciences signs US distribution agreement with Diagnostica Stago; shares ahead 14% premarket|
seekingalpha.com - March 26 at 5:12 PM
|Akers Bio signs 3-year distribution deal with Diagnostica Stago|
finance.yahoo.com - March 26 at 5:12 PM
|Akers Biosciences (AKER) Enters US Distribution Agreement with Diagnostica Stago|
www.streetinsider.com - March 26 at 8:29 AM
|BRIEF-Akers Biosciences Signs Distribution Agreement With Diagnostica Stago|
www.reuters.com - March 26 at 8:29 AM
|Akers Biosciences Signs US Distribution Agreement with Diagnostica Stago|
finance.yahoo.com - March 26 at 8:29 AM
|Consolidated Research: 2018 Summary Expectations for Brixmor Property Group, First Majestic Silver, Barclays, Akers Biosciences, Precision Drilling, and NBT — Fundamental Analysis, Key Performance Indications|
finance.yahoo.com - March 26 at 8:29 AM
|Akers Biosciences (AKER) Set to Announce Quarterly Earnings on Thursday|
www.americanbankingnews.com - March 22 at 1:34 AM
|Akers Biosciences Nets USD49,000 From Warrants Exercise (ALLISS)|
www.morningstar.co.uk - March 16 at 6:24 PM
|Akers Biosciences Announces Conference Call to Discuss Fiscal Year 2017 Earnings - GlobeNewswire (press release)|
globenewswire.com - March 16 at 8:27 AM
|Akers Biosciences Issues 1.5 Million Shares After Warrants Exercise (ALLISS)|
www.morningstar.co.uk - March 2 at 6:03 PM
|Did Akers Biosciences Inc’s (NASDAQ:AKER) Earnings Growth Outperform The Industry?|
finance.yahoo.com - March 1 at 8:20 AM
|Akers Biosciences Shares Bouncing Back, New Self Diagnostic Products Being Developed|
finance.yahoo.com - February 26 at 8:24 AM
|Akers Biosciences Receives USD882,281 After Share Warrant Exercise (ALLISS)|
www.morningstar.co.uk - February 16 at 5:14 PM
|Akers Biosciences Inc (AKER) Sees Large Growth in Short Interest|
www.americanbankingnews.com - February 9 at 5:26 PM
|Akers Biosciences Issues 11.4 Million Shares After Warrants Exercise (ALLISS)|
www.morningstar.co.uk - February 9 at 4:01 PM
|Akers Biosciences Nets USD95,625 From Warrant Exercise (ALLISS)|
www.morningstar.co.uk - February 2 at 3:52 PM
|Akers Biosciences Issues 2.8 Million Shares After Warrants Exercise (ALLISS)|
www.morningstar.co.uk - January 26 at 9:50 AM
|Short Interest in Akers Biosciences Inc (AKER) Declines By 63.3%|
www.americanbankingnews.com - January 14 at 3:40 AM
|Akers Biosciences Gets Conversion Notice Worth 9.4 Million Shares (ALLISS)|
www.morningstar.co.uk - January 13 at 3:50 PM
|2 Healthcare Testing & Diagnostic Stocks Taking Center Stage Ahead of JP Morgan Conference|
finance.yahoo.com - January 9 at 3:55 PM
|Akers Biosciences, Inc. :AKER-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017|
finance.yahoo.com - December 25 at 4:41 PM
|BRIEF-Alpha Capital Anstalt Reports 9.9 Pct Passive Stake In Akers Biosciences|
www.reuters.com - December 22 at 5:27 PM
|Akers Biosciences To Raise USD6.0 Million In Open Offer (ALLISS)|
www.morningstar.co.uk - December 19 at 3:53 PM
|Here’s Why Akers Biosciences Inc (AKER) Shares Are Collapsing|
finance.yahoo.com - December 19 at 3:53 PM
|ValuEngine Upgrades Akers Biosciences (AKER) to Hold|
www.americanbankingnews.com - December 4 at 12:22 AM
|What Is Akers Biosciences Inc’s (AIM:AKR) Share Price Doing?|
finance.yahoo.com - November 28 at 10:40 AM
|Akers Biosciences Inc (AKER) Issues Earnings Results|
www.americanbankingnews.com - November 16 at 9:16 AM
|Akers Biosciences' UK Distributor Secures New Channel For Rapid Alcohol Breathalyzer|
www.thestreet.com - November 14 at 9:11 PM
|BRIEF-Akers Biosciences - Accutest Solutions secured new channel partner for sales|
www.reuters.com - November 14 at 4:10 PM
|Akers Biosciences’ UK Distributor Secures New Channel for Rapid Alcohol Breathalyzer|
finance.yahoo.com - November 14 at 4:10 PM
|Akers Biosciences Announces Conference Call to Discuss Q3 2017 Earnings|
finance.yahoo.com - November 14 at 2:51 AM
|Have Investors Already Priced In Akers Biosciences Inc’s (AKER) Growth?|
finance.yahoo.com - November 14 at 2:51 AM
Akers Biosciences (NASDAQ:AKER) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Akers Biosciences (NASDAQ:AKER) Income Statement, Balance Sheet and Cash Flow Statement
Akers Biosciences (NASDAQ AKER) Stock Chart for Wednesday, May, 23, 2018